Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA
GERMANTOWN, Maryland, Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will begin trading on the Nasdaq Capital Market under the ticker symbol, NASDAQ: SNCA beginning onN...
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases
GERMANTOWN, Maryland, Oct. 30, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (fka Neuralstem, Inc.) (NASDAQ: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, and Jiangsu QYuns Therapeutics Co., Ltd., aChina-based company focused on m...
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit
GERMANTOWN, Maryland, Oct. 29, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (fka Neuralstem, Inc) (NASDAQ: CUR) a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will present at the 7th China Renaissance Healthcare and Life Sciences Leaders...
